Monday, February 22, 2021 Daily Archives

CDMO to build $490m MAb plant as GSK exits UK site

by

Lakes BioScience has received permission to begin building a £350 million biomanufacturing facility at a site in Ulverston, UK, currently owned by GSK. Last week, South Lakeland District Council granted permission for Lakes Bioscience, a recently formed biomanufacturing firm, to build a new facility on GlaxoSmithKline’s (GSK) site located on North Lonsdale Road, Ulverston, Cumbria. Lakes BioScience director, Pat McIver told BioProcess Insider it is investing £350 million ($490 million) to build a new site which will produce monoclonal antibodies…

February 22, 2021

Emergent CDMO biz ‘thriving’ in COVID-19 environment

by

The COVID-19 pandemic has highlighted the growing mammalian and viral vaccines market and placed Emergent in a “leading position†in the CDMO space, says CEO Bob Kramer. The fourth quarter 2020 produced record revenues for Emergent BioSolutions, with the firm reporting sales of $583 million, up 62% on the year prior. For the full year, sales tallied $1.56 billion, up 41% on 2019. While Emergent has its own product line (contributing $340 million in the quarter, with its smallpox vaccine…

February 22, 2021

Ensoma launches to deliver ‘off-the-shelf’ genomic medicine

by

Ensoma emerges with Series A funding and a collaboration deal with Takeda for its vector-delivered treatments. Ensoma was backed in its Series A financing by 5AM Ventures and Takeda, amongst other investors, with $70 million (€57 million). Takeda’s investment occurs alongside an exclusive worldwide license to develop Ensoma’s ‘Engenious’ vectors for up to five rare disease indications. The agreement includes a potential $100 million investment in upfront and preclinical research payments. Should the candidates progress past the preclinical stage, Ensoma…

February 22, 2021